Synthesis and Biological Evaluation of Some Substituted-2-<i>N</i>-(5-chloro-2-methoxy-4-methylphenylsulphonyl) Glutamic Acid Derivatives against Prostate Cancer Cell Line PC3
作者:Ghaneya Sayed Hassan、Doaa Ezzat Abdel Rahman
DOI:10.1248/cpb.c12-00881
日期:——
New series of substituted glutamine 5a–l and glutamic acid diamides, diureide and dihydrazide 7a–e were synthesized from parent glutamic acid compound 3 and evaluated for their cytotoxic activity against tumor cell line PC3 (prostate cancer cell line). Most of the tested compounds exploited potent growth inhibitory activity with IC50 values ranging 0.034–3.97 µM. Particularly, compounds 5a, 3, 5j, 5b, 7c, 7e, 5l, and 5k exhibited superior potency (IC50=0.034, 0.04, 0.05, 0.074, 0.25, 0.4, 0.49, 0.522 µM, respectively) to the reference drug Doxorubicin (IC50=0.63 µM), while compound 7b showed IC50, 0.71 µM, comparable to that of Doxorubicin. In summary, the newly synthesized compounds provided promising new lead for the future design and development of glutamine and glutamic acid derivatives as novel antitumor agents. The quantitative structure–activity relationship (QSAR) study was applied to find a mathematical correlation between the structures of compounds and their activity against PC3 cell line expressed as IC50 values.
从母体谷氨酸化合物 3 合成了一系列新的取代谷氨酰胺 5a-l 和谷氨酸二酰胺、利尿剂和二酰肼 7a-e,并评估了它们对肿瘤细胞系 PC3(前列腺癌细胞系)的细胞毒活性。大多数受测化合物都具有很强的生长抑制活性,IC50 值为 0.034-3.97 µM。特别是化合物 5a、3、5j、5b、7c、7e、5l 和 5k 显示出卓越的效力(IC50=0.034、0.04、0.05、0.074、0.25、0.4、0.49、0.522µM)优于参考药物多柔比星(IC50=0.63µM),而化合物 7b 的 IC50 为 0.71 µM,与多柔比星相当。总之,新合成的化合物为今后设计和开发谷氨酰胺和谷氨酸衍生物作为新型抗肿瘤药物提供了新的线索。通过定量结构-活性关系(QSAR)研究,找到了化合物结构与它们对 PC3 细胞系的活性之间的数学相关性(以 IC50 值表示)。